Buy this domain.
Avastin Side Effects Make it too Risky as a Breast Cancer Treatment, FDA Panel Says | cialis online

Avastin Side Effects Make it too Risky as a Breast Cancer Treatment, FDA Panel Says

AddThis Social Bookmark Button

Avastin should not be approved to treat patients with advanced breast cancer, a Food & Drug Administration (FDA) advisory panel said yesterday.   The panel voted 5-4 to recommend that the FDA reject Genentech’s application to expand the approved uses of Avastin to include metastatic breast cancer patients because the drug maker was unable to prove that the benefits of the drug outweighed its serious side effects.

Avastin was approved by the FDA in 2004 to treat colon cancer, and in 2006, the agency approved it as a treatment for non-small cell lung cancer.   Avastin was the first approved therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor. Avastin has been a blockbuster for Genentech, and its parent company Roche AG.  For the first nine months of 2007, US sales of Avastin topped $1 billion, accounting for 27% of Genentech’s overall product sales.  Some analysts believe that if Avastin is approved to treat metastatic cancer – cancer that has spread to other parts of the body – sales of the medication could grow by $1.9 billion by 2009.

But hopes that the FDA would approve Avastin for metastatic breast cancer where dimmed last week when agency staff posted documents noting that while the medication did extend the period prior to patients’ breast cancer becoming worse, treatment with the drug did not markedly increase survival time.  The FDA documents also pointed out that Avastin caused serious side effects, including cardiovascular problems, bowel perforations, and a few deaths. The FDA staff said that those side effects included 5 patient deaths that were “probably or definitely” due to Avastin. While the FDA Avastin review did not include an opinion on Avastin’s breast cancer approval, the agency’s staff did recommend that the benefits of Avastin in treating breast cancer be weighed against its risks.

The FDA advisory panel had to decide whether it is valid to approve a drug that failed to extend lives, although it showed a capacity to slow tumors. The FDA sometimes approves cancer drugs on what are known as surrogate markers, such as slowing the spread of tumors, instead of waiting for survival data that can take years to collect.

Representatives from Genentech argued for the approval of Avastin as a breast cancer treatment because its effect on tumor growth could improve the quality of life for these patients, even if the drug did not extend their lives.   But some FDA advisors clearly felt that this benefit did not justify Avastin’s many risks.  “These patients are terminal, and it’s our job to make their lives better, not to say that it’s OK to have a stroke or that it’s manageable,” said Maha Hussain, an oncologist at the University of Michigan and the advisory panel’s chairwoman. 

The FDA advisory panel vote is an indication that the agency is finally taking a tougher stance on drug approvals.  Over the past few years, safety scandals involving Vioxx, Avandia and other drugs have led to criticisms that the FDA was too quick with approvals, and often ignored serious side effects. 

The FDA is not obligated to follow the recommendations of its advisory panels, but usually does so.  A decision on the expanded use of Avastin is expected by February.

« »

Leave a Reply

You must be logged in to post a comment.




Defective Johnson & Johnson Depuy ASR Hip Implants

The Johnson & Johnson Depuy ASR Hip Implant is suppose to last 15 years, but can fail in only a few years after surgery. Victims with faulty hip implants endure excruciating pain, pain in the groin, death of tissue in the hip joint and loss of surrounding bone. GET ALL THE FACTS NOW! CLICK HERE!

CAT Scans Radiation Exposure

If you had a CT or CAT scan and now have a band of missing hair, skin reddening or any other problems possibly related to a radiation overdose, you may have been exposed to much radiation due to incorrect settings on these machines. CONTACT US TODAY!

Water Contamination From Fracking

Hydraulic Fracturing of Fracking a way to extract natural gas from shale is contaminating water supplies across the country. Get the facts to keep your drinking water safe for your family.

Overexposure to PCBs

Many people unknowingly have been exposed to high levels of PCBs. Recently 3 schools in NY City were found to have dangerous levels of PCBs throughout. Many workers for Monsanto, General Electric, and Westinghouse were exposed to high levels of PCBs. PCBs are a dangerous toxic substance that doesn't break down easily and can cause chloracne, bleeding and neurological disorders, liver damage, spontaneous abortions, malformed babies, cancer, and death. GET THE FACTS!
Overexposure to

Great Photography

Tallis Photo, the number one photographer for great corporate, wedding, and special occasion photos. CONTACT US TODAY!

Poligrip Lawsuit

Super Poligrip or Fixodent May Cause Nerve Damage. 800-LAW-INFO

Personal Injury Lawyer Nassau County

If you or someone you love was injured CONTACT US TODAY!

Nursing Home Blog

When a loved one is abused at a nursing home, it is time to take action. STOP nursing home abuse!

Car Accident Lawyer Nassau County

If you or someone you love was injured in an auto accident CONTACT US TODAY!

Suffolk County Auto Accident Lawyer

If you or someone you love was injured in an auto accident in Suffolk County, NY CONTACT US TODAY!

Don't Be Denied Veterans Benefits

If you or someone you love was denied veterans benefits CONTACT US TODAY!

Oil Rig Spills Lawyer

Oil Rig Spills harm the environment and cause heavy losses to coastal game and fishing industries, as well as a loss of waterway usage, resulting in a loss of income to individuals and businesses, and a loss of beach front usage. Don't let a spill cause you harm, CONTACT US TODAY!

Whistle Blower

Stand up and say what you think is right. See something, say something.